These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14652981)

  • 21. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
    Mah GT; Mabasa VH; Chow I; Ensom MH
    Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.
    Halstenson CE; Wong MO; Johnson CA; Zimmerman SW; Onorato JJ; Keane WF; Doepner M; Sia L; Tantillo K; Bansal S
    J Clin Pharmacol; 1994 Dec; 34(12):1208-17. PubMed ID: 7738217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and implementation of a piperacillin-tazobactam extended infusion guideline.
    Heinrich LS; Tokumaru S; Clark NM; Garofalo J; Paek JL; Grim SA
    J Pharm Pract; 2011 Dec; 24(6):571-6. PubMed ID: 21676847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adding piperacillin-tazobactam to automated dispensing cabinets on promptness of first-dose antibiotics in hospitalized patients.
    Lo A; Zhu JN; Richman M; Joo J; Chan P
    Am J Health Syst Pharm; 2014 Oct; 71(19):1663-7. PubMed ID: 25225451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
    McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
    Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
    Marra FO; Frighetto LO; Marra CA; Sleigh KM; Stiver HG; Bryce EA; Reynolds RP; Jewesson PJ
    Ann Pharmacother; 1999 Feb; 33(2):156-62. PubMed ID: 10084409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK; Grupper M; Nicolau DP; Kuti JL
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP; Kumar R; Carmeli Y
    Pharmacoeconomics; 2009; 27(12):1045-56. PubMed ID: 19908928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.
    Yang H; Cui X; Ma Z; Liu L
    J Pharm Pharm Sci; 2016; 19(2):274-89. PubMed ID: 27518175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.
    Jhee SS; Gill MA; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Clin Ther; 1995; 17(1):126-35. PubMed ID: 7758055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
    Sumi CD; Heffernan AJ; Naicker S; Islam K; Cottrell K; Wallis SC; Lipman J; Harris PNA; Sime FB; Roberts JA
    J Antimicrob Chemother; 2020 Sep; 75(9):2633-2640. PubMed ID: 32585693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
    Edwards SJ; Wordsworth S; Clarke MJ
    Eur J Health Econ; 2012 Apr; 13(2):181-92. PubMed ID: 21243514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
    Palau J; Picón I; Aznar E; Climent MA; Máiquez J
    Rev Esp Quimioter; 2000 Jun; 13(2):193-8. PubMed ID: 10918094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients.
    Rotschafer JC; Ullman M
    Ann Pharmacother; 2009 Nov; 43(11):1887-9. PubMed ID: 19809005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.